KA
VRTX icon

Kintegral Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Kintegral Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.86M Sell
6,397
-284
-4% -$132K 0.27% 99
2025
Q4 		$3.03M Sell
6,681
-183
-3% -$78.9K 0.26% 98
2025
Q3 		$2.69M Sell
6,864
-31
-0.4% -$13K 0.23% 109
2025
Q2 		$3.07M Sell
6,895
-10
-0.1% -$4.61K 0.28% 93
2025
Q1 		$3.35M Sell
6,905
-23
-0.3% -$10.7K 0.34% 89
2024
Q4 		$2.79M Sell
6,928
-323
-4% -$150K 0.26% 99
2024
Q3 		$3.37M Sell
7,251
-95
-1% -$45.6K 0.31% 94
2024
Q2 		$3.44M Sell
7,346
-2,748
-27% -$1.19M 0.33% 90
2024
Q1 		$4.22M Sell
10,094
-31
-0.3% -$13.1K 0.42% 68
2023
Q4 		$4.12M Sell
10,125
-64
-0.6% -$23.6K 0.46% 56
2023
Q3 		$3.54M Sell
10,189
-6
-0.1% -$2.1K 0.44% 66
2023
Q2 		$3.59M Hold
10,195
– – 0.43% 71
2023
Q1 		$3.21M Sell
10,195
-548
-5% -$164K 0.41% 77
2022
Q4 		$3.1M Sell
10,743
-3,912
-27% -$1.19M 0.41% 83
2022
Q3 		$4.24M Hold
14,655
– – 0.59% 40
2022
Q2 		$4.13M Buy
14,655
+310
+2% +$83K 0.54% 45
2022
Q1 		$3.74M Buy
14,345
+320
+2% +$75.9K 0.41% 56
2021
Q4 		$3.08M Hold
14,025
– – 0.32% 75
2021
Q3 		$2.54M Hold
14,025
– – 0.3% 80
2021
Q2 		$2.83M Hold
14,025
– – 0.33% 72
2021
Q1 		$3.01M Hold
14,025
– – 0.39% 68
2020
Q4 		$3.31M Hold
14,025
– – 0.45% 57
2020
Q3 		$3.82M Sell
14,025
-451
-3% -$124K 0.58% 41
2020
Q2 		$4.2M Hold
14,476
– – 0.68% 34
2020
Q1 		$3.44M Buy
14,476
+1,619
+13% +$371K 0.67% 39
2019
Q4 		$2.81M Hold
12,857
– – 0.51% 54
2019
Q3 		$2.18M Hold
12,857
– – 0.43% 68
2019
Q2 		$2.36M Hold
12,857
– – 0.48% 56
2019
Q1 		$2.37M Sell
12,857
-156
-1% -$28.8K 0.5% 55
2018
Q4 		$2.16M Buy
+13,013
New +$2.25M 0.64% 40

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Kintegral Advisory's VRTX Position: Q1 2026 in Review

Kintegral Advisory reduced its Vertex Pharmaceuticals (VRTX) stake by 4.3% in Q1 2026, selling an estimated $132K and leaving 6,397 shares worth $2.86M. The position accounts for 0.27% of the portfolio, ranked #99.

Kintegral Advisory first reported a position in VRTX in Q4 2018 and has held it in 30 quarters since. The position peaked at $4.24M in Q3 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Kintegral Advisory held 6,397 shares of Vertex Pharmaceuticals worth $2.86M as of Q1 2026.
  • Kintegral Advisory sold 284 Vertex Pharmaceuticals shares in Q1 2026, an estimated $132K.
  • Vertex Pharmaceuticals made up 0.27% of Kintegral Advisory's portfolio in Q1 2026, its #99 holding.
  • Kintegral Advisory first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
  • Kintegral Advisory's Vertex Pharmaceuticals position peaked at $4.24M in Q3 2022.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Kintegral Advisory's 13F filing for Q1 2026, filed 14 May 2026.